|
1
|
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
|
Blood
|
2006
|
4.46
|
|
2
|
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
|
Proc Natl Acad Sci U S A
|
2008
|
4.43
|
|
3
|
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
|
Proc Natl Acad Sci U S A
|
2009
|
1.34
|
|
4
|
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
|
Blood
|
2005
|
1.24
|
|
5
|
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
|
Biol Blood Marrow Transplant
|
2002
|
1.23
|
|
6
|
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
7
|
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.05
|
|
8
|
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
|
Blood
|
2002
|
1.02
|
|
9
|
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
|
Clin Cancer Res
|
2002
|
0.90
|
|
10
|
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
|
Cancer Res
|
2003
|
0.90
|
|
11
|
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
|
Am J Hematol
|
2008
|
0.89
|